ClinicalTrials.gg
CompletedNCT03273712Updated Feb 9, 2023Results posted

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

A Phase 2 interventional study of 90Y-DOTA tyr3-Octreotide and 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan in Neuroendocrine Tumors, Meningioma and Neuroblastoma, sponsored by University of Iowa. Completed at 1 site in United States. Open to participants aged 6 Months to 90 Years. Per ClinicalTrials.gov, last updated 2023-02-09.

Sponsored by University of Iowa · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
6 Months to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 219 studies in Neuroendocrine Tumors with a site in United States — 45 open to participants now, 77 under way, 10 of them phase 3. Neuroendocrine Tumors · United States.

Enrollment
89th of 190
39 · median 35
Started
2017
with 21 others
Phase 2
83 of 219
12 open now
Registered
115th of 219
by date

Among the 219 studies in Neuroendocrine Tumors with a site in United States, this one is the 89th largest by enrollment of the 190 interventional ones that give a count, is one of 22 that started in 2017, is one of 83 in phase 2, and was the 115th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 137 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

45 of the 219 studies in Neuroendocrine Tumors with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 6 Months to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Neuroendocrine Tumors with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.

Read the detailed description

This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors. The somatostatin receptor targeting of the therapeutic will be checked with 68Ga-DOTATOC PET-CT imaging prior to therapy. Treatment consists of 3 cycles, 6-8 weeks apart. Cycle 1 dose is fixed with Cycles 2 and 3 doses to be determined by dosimetry-based calculation of renal doses from previous cycles not to exceed 23 Gy for the total renal dose.

The goals of this project are to

  1. Demonstrate the safety and efficacy of dosimetry-guided peptide receptor radiotherapy using 90Y-DOTA-tyr3-Octreotide in patients with neuroendocrine and other somatostatin receptor expressing tumors.
  2. Monitor all adverse events associated with peptide receptor radiotherapy using 90Y-DOTATOC.
  3. Establish 68Ga-DOTA-tyr3-Octreotide (68Ga-DOTATOC) or 68Ga-DOTATATE PET/CT as an accurate technique for diagnosis, staging, treatment targeting, and monitoring response to 90Y-DOTATOC therapy.
03

Conditions studied

  • Neuroendocrine Tumors
  • Meningioma
  • Neuroblastoma
  • Medulloblastoma
04

Who can participate

Ages eligible
6 Months to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Disease not amenable to standard treatment (nonresectable or disease present after one or more surgeries and/or Sandostatin treatment) or subject has failed existing chemotherapy, biologic therapy, targeted agent therapy or radiation therapy.
  2. Participation in Iowa Neuroendocrine Tumor Registry.
  3. A confirmed (histology or cytology) malignant neoplasm with at least one target lesion that is confirmed by conventional imaging and is determined to express somatostatin receptors by 68Ga-DOTATOC (TATE) PET within 6 months prior to treatment with 90Y-DOTATOC.
  4. The target lesion is one that either has never received external beam radiation or has been previously irradiated and has since demonstrated progression. Any local irradiation of the target lesion or any non-target lesions via external beam, conformal or stereotactic radiation treatments must have occurred more than 4 weeks prior to study drug administration. Any full cranial-spinal radiation, whether or not a target lesion is included in the field, must have occurred more than 3 months prior to study drug administration.
  5. > 2 months at the time of study drug administration.
  6. from a previous biopsy will be required.
  7. Age ≥ 6 months-90 years at the time of study drug administration.
  8. Performance status as determined by ≥ 60 or Lansky Play Scale ≥ 60% at the time of study drug administration.
  9. Completion of Norfolk Quality of Life Questionnaire.
  10. Within 7-10 days of study drug administration, patients must have normal organ and marrow function as defined below:

    • >1000/mm3
    • >90,000/mm3
    • total \<3X for age
    • (SGOT) \& ALT(SGPT) \<10X institutional upper limit of normal for age
    • Urinalysis no greater than 1+ hematuria or proteinuria
    • Renal function* Adults(age18 or >): Serum creatinine ≤ 1.2 mg/dl; if serum creatinine is >1.2 mg/dL, nuclear will be measured. GFR will need to be ≥ 80 ml/min/1.73m2 for subjects ≤40 years old, ≥ 70 ml/min/1.73m2 for subjects between 41-50; ≥ 60 ml/min/1.73m2 for subjects between 51-60; ≥ 50 ml/min/1.73m2 for subjects > 60 years old.

    Children(age \<18): nuclear GFR ≥ 80 mL/min/1.73 m2

    * Renal function criteria based on our previous experience with 90Y-DOTATOC therapy and known changes in GFR with age13,21,33-35

  11. The effects of 90Y-DOTA-tyr3-Octreotide on the developing human fetus are unknown. For this reason and because Class C agents are known to be teratogenic, women and men of must agree to use adequate (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  12. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women are excluded from this study because 90Y-DOTATOC is a Class C agent with potential teratogenic or abortifacient effects.
  2. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 90Y-DOTATOC, breastfeeding should be discontinued until 6 weeks after the last administration of study drug.
  3. Surgery within 4 weeks of study drug administration.
  4. External beam radiation to both kidneys (scatter doses of \<500 cGy to a single kidney or radiation to \< 50% of a single kidney is acceptable).
  5. Prior PRRT with 90Y-DOTATOC (TATE) or 177Lu-DOTATOC (TATE) or 131I-MIBG therapy for this .
  6. Another drug within 4 weeks of study drug administration.
  7. Concurrent, malignant disease for which patient is on active therapy.
  8. Another significant medical, psychiatric, or surgical condition which is currently uncontrolled by treatment and which would likely affect the subject's ability to complete this protocol.
  9. Any subject for whom, in the opinion of their physician, a 12-hour discontinuation of somatostatin analogue therapy represents a health risk. Also subjects who have received SandostatinLAR in the past 28 days or long-acting lanreotide within the past 8 weeks are excluded. Subjects may be maintained on short acting octreotide during the time from last injection of long-acting somatostatin analogue until 12 hrs prior to injection of study drug. Known antibodies to Octreotide, Lanreotide, or DOTATOC or history of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-DOTATOC.
  10. Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of study drug administration or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  11. Uncontrolled illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  12. Subject weighs more than 450 pounds. (Subjects who weigh more than 450 pounds will not be able to fit inside the imaging machines.)
  13. Inability to lie still for the entire imaging time (due to cough, severe arthritis, etc.)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    90Y-DOTA-tyr3-Octreotide

    Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.

    Radiation: 90Y-DOTA tyr3-Octreotide · Diagnostic Test: 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan · Drug: Amino Acids

Interventions

  • Radiation90Y-DOTA tyr3-Octreotide

    90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.

    Also known as: 90Y-DOTATOC

  • Diagnostic test68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan

    68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.

  • This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.

    Also known as: Lysine and Arginine

06

What researchers measure

Primary outcomes

  1. Frequency of Tumor Response at 9 Months After Last Treatment

    Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) was used to quantify tumor response by comparison of baseline and last follow-up visit (6-9 months after last treatment) diagnostic CT/MRI scans.

    Time frame: Baseline through last follow-up visit (6-9 months after last treatment), up to approximately 10-13 months.

  2. Percentage of Patients With Grade 4 or Higher Renal Adverse Event.

    The percentage of patients who experience a grade 4 or higher renal adverse event. Renal adverse events were graded using CTCAE v4.0 criteria.

    Time frame: Initiation of treatment through last follow-up visit (6-9 months after last treatment), up to approximately 10-13 months.

  3. Percentage of Patients With Grade 4 or Higher Irreversible Adverse Events

    The percentage of patients who experience a grade 4 or higher irreversible adverse event. Adverse events were graded using CTCAE v4.0 criteria.

    Time frame: Initiation of treatment through last follow-up visit (6-9 months after last treatment), up to approximately 10-13 months.

07

Results

Posted Feb 9, 2023

Participant flow

The University of Iowa Neuroendocrine Tumor Registry includes over 1500 individuals with NETs who have signed consent to be contacted when new clinical trials are available. The University of Iowa Children's Hospital has children with neuroblastoma and medulloblastoma (or other brain tumor) and neuroendocrine tumor who may be interested; in this case, participation would be offered only if/when the child failed conventional therapy.

Participant flow — Overall Study
Milestone90Y-DOTA-tyr3-Octreotide
Started39
Completed32
Not completed7
Withdrew: Death5
Withdrew: Adverse event1
Withdrew: Disease progression1

Outcome measures

PrimaryFrequency of Tumor Response at 9 Months After Last Treatment

Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) was used to quantify tumor response by comparison of baseline and last follow-up visit (6-9 months after last treatment) diagnostic CT/MRI scans.

Time frame:
Baseline through last follow-up visit (6-9 months after last treatment), up to approximately 10-13 months.
Reported as:
Count of participants · Participants
Frequency of Tumor Response at 9 Months After Last Treatment
Participants90Y-DOTA-tyr3-Octreotide
Complete Response0
Partial Response1
Stable Disease19
Progressive Disease15
Not Evaluable4
PrimaryPercentage of Patients With Grade 4 or Higher Renal Adverse Event.

The percentage of patients who experience a grade 4 or higher renal adverse event. Renal adverse events were graded using CTCAE v4.0 criteria.

Time frame:
Initiation of treatment through last follow-up visit (6-9 months after last treatment), up to approximately 10-13 months.
Reported as:
Count of participants · Participants
Percentage of Patients With Grade 4 or Higher Renal Adverse Event.
Participants90Y-DOTA-tyr3-Octreotide
Percentage of Patients With Grade 4 or Higher Renal Adverse Event.0
PrimaryPercentage of Patients With Grade 4 or Higher Irreversible Adverse Events

The percentage of patients who experience a grade 4 or higher irreversible adverse event. Adverse events were graded using CTCAE v4.0 criteria.

Time frame:
Initiation of treatment through last follow-up visit (6-9 months after last treatment), up to approximately 10-13 months.
Reported as:
Count of participants · Participants
Percentage of Patients With Grade 4 or Higher Irreversible Adverse Events
Participants90Y-DOTA-tyr3-Octreotide
Percentage of Patients With Grade 4 or Higher Irreversible Adverse Events0

Adverse events

Collected over Adverse even documentation began after radiotracer injection and continues through 1 calendar day following imaging, up to approximately 10-13 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
90Y-DOTA-tyr3-Octreotide5/39 (12.8%)14/39 (35.9%)37/39 (94.9%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
Event90Y-DOTA-tyr3-Octreotide
Small intestinal obstructionGastrointestinal disorders2/39
SepsisInfections and infestations2/39
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specifyNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/39
AnemiaBlood and lymphatic system disorders1/39
Atrioventricular block completeCardiac disorders1/39
Endocrine disorders - Other, specifyEndocrine disorders1/39
NauseaGastrointestinal disorders1/39
Edema limbsGeneral disorders1/39
PainGeneral disorders1/39
Bronchial infectionInfections and infestations1/39
Most frequent other events
Showing 10 of 74
Most frequent other events
Event90Y-DOTA-tyr3-Octreotide
NauseaGastrointestinal disorders37/39
VomitingGastrointestinal disorders15/39
FatigueGeneral disorders15/39
Abdominal painGastrointestinal disorders9/39
HeadacheNervous system disorders8/39
AnemiaBlood and lymphatic system disorders7/39
DizzinessNervous system disorders6/39
FeverGeneral disorders5/39
Infusion site extravasationGeneral disorders5/39
Lymphocyte count decreasedInvestigations5/39

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)90Y-DOTA-tyr3-Octreotide
<=18 years4
Between 18 and 65 years24
>=65 years11
Age, Continuous
Age, Continuous(years)90Y-DOTA-tyr3-Octreotide
Mean54 (9 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)90Y-DOTA-tyr3-Octreotide
Female19
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)90Y-DOTA-tyr3-Octreotide
Hispanic or Latino0
Not Hispanic or Latino39
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)90Y-DOTA-tyr3-Octreotide
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White37
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)90Y-DOTA-tyr3-Octreotide
United States39
08

Study locations

1 site
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in May 2020, 31 months.

Results were first posted in Feb 2023, 2 years 8 months after primary completion.

Of 85 non-industry phase 2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 83. This study's 31 months is below that.

Counting every sponsor, half of 98 studies reached it within 65 months; a quarter within 42 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2017
First posted
Sep 6, 2017
StartActual
Sep 29, 2017
Primary completionActual
May 27, 2020
CompletionActual
May 27, 2020
Results first posted
Feb 9, 2023
Last update
Feb 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03273712
Lead sponsor
University of Iowa
Responsible party
Sue O'Dorisio (Professor, University of Iowa) — Principal investigator
First posted
Sep 6, 2017
Start date
Sep 29, 2017
Primary completion
May 27, 2020
Completion
May 27, 2020
Results posted
Feb 9, 2023
Last update
Feb 9, 2023

Study contacts

M. Sue O'Dorisio, MD, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amino Acids

Start the discussion